PU21.03 Assessment of crosslinker suitability for fusion peptide conjugates as priming immunogens for an HIV-1 vaccinePublication OnlyNovel vaccine and other prevention approaches
PE16.04 Assessing the use of surveillance data to estimate reductions in HIV incidence achieved by combination HIV prevention programs: a mathematical modelling studyE-posterImplementation science, including structural interventions, PrEP & VMMC
PE01.38 Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on PrEP persistence among adolescent girls in HPTN 082E-posterBehavioural and social science research
PE16.38LB Applying statistical control processes to characterize the variations in occurrence of adverse events in VMMC delivery in ZimbabweE-posterImplementation science, including structural interventions, PrEP & VMMC
OA09.04 Applying insights from HIV to guide the development of a T-cell vaccine for SARS-CoV-2Oral Abstract SessionCOVID research: Applying lessons from HIV prevention to SARS CoV-2
PE08.09LB Anti-HPV and anti-HSV activity in rectal enema effluents collected from subjects receiving PC-1005: a dual compartment multipurpose prevention technology formulationE-posterDelivery technologies: novel approaches, formulation and multi-purpose
OA09.02 Anti-Env antibody-independent protection of repeated intrarectal low-dose SIVmac239 challenges in rhesus macaques by vaccination inducing Gag/Vif-specific CD8+ T but not CD4+ T cellsOral Abstract SessionMucosal immunity
PE08.05 Anti-CCR5 siRNA-loaded polymeric nanoparticles for topical pre-exposure prophylaxisE-posterDelivery technologies: novel approaches, formulation and multi-purpose
PE02.03 Antibody-Antigen Distance of Broadly Neutralizing HIV-1 Antibodies Correlates with Glycan-Shield Coverage of HIV-1 Envelope TrimerE-posterBroadly neutralizing antibodies
OA08.01 Antibody isotype switching as a mechanism to counter HIV neutralization escapeOral Abstract SessionHumoral immunity
seek-warrow-warrow-eseek-e401 - 410 of 444 items